Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib

Yuhang Zhou, Marisabel Hurtado-Castillo, Om PandeyFrontiers in Medicine 2023 · DOI

This case report, published in Frontiers in Medicine, details a landmark clinical finding: the first documented case of ALK-positive histiocytosis (APH) presenting as synchronous bilateral breast masses. By leveraging next-generation sequencing to identify a specific genetic driver, clinicians achieved complete, long-term remission using a targeted ALK inhibitor, crizotinib, providing a blueprint for treating this exceptionally rare disease.

TL;DR

Researchers report the first case of ALK-positive histiocytosis presenting as bilateral breast masses, successfully treated with the targeted inhibitor crizotinib. The study highlights how molecular profiling can turn a complex, multi-organ systemic disease into a manageable condition with long-term remission.

What Problem Does This Paper Address?

Histiocytic neoplasms are rare disorders where histiocytes—a type of immune cell—proliferate abnormally. APH is a particularly elusive subtype, first defined in 2008, driven by mutations in the Anaplastic Lymphoma Kinase (ALK) gene.

The primary challenge addressed here is diagnostic mimicry. APH can manifest in the liver, lungs, brain, or skin, often leading to misdiagnosis. In this specific case, a 46-year-old woman presented with bilateral breast masses and nipple ulceration. To a clinician, this looks like primary breast cancer or metastatic malignancy. Because only 27 cases of APH had been reported in the literature prior to this study, it is rarely the first suspicion. This paper aims to expand the clinical "map" of APH symptoms and demonstrate the efficacy of targeted therapy over traditional, more invasive treatments.

Methods

The clinicians used a multi-modal diagnostic approach to differentiate the masses from common breast cancers:

  • Imaging: Mammography (categorized as BI-RADS 4C, high suspicion for malignancy), MRI, and CT scans to map systemic involvement.
  • Histopathology: Biopsies of the breast and lung nodules.
  • Immunohistochemistry (IHC): Staining for specific markers. The cells tested positive for ALK1, CD163, and CD68, which are hallmarks of histiocytic proliferation.
  • Next-Generation Sequencing (NGS): Using the FoundationOne CDx platform, the team identified a KIF5B-ALK gene fusion. This was the "smoking gun" that confirmed the APH diagnosis and pointed toward a specific treatment.
  • Targeted Therapy: Instead of surgery or chemotherapy, the patient was prescribed 250 mg of crizotinib (an ALK inhibitor) twice daily.

Datasets

As a clinical case report, this study does not utilize large-scale training datasets. However, it contributes to the global medical knowledge base by adding to the very small pool of ~30 known APH cases. The authors performed a literature review of these existing cases to contextualize their findings regarding age distribution and organ involvement.

Key Insights and Ideas

  • Bilateral Presentation: This is the first time APH has been shown to affect both breasts simultaneously at initial presentation. Previously, breast involvement was rare and usually unilateral.
  • The Power of NGS: Traditional pathology might have labeled this as an "atypical" histiocytic proliferation. NGS provided the definitive molecular target (KIF5B-ALK), which is also a common driver in certain lung cancers.
  • Systemic Efficacy: The disease was not just in the breasts; it had spread to the lungs, brain (caudate head), and bones (skull, femur, sternum). The targeted inhibitor crizotinib was able to clear the disease across all these disparate sites simultaneously.
  • Shift in Treatment Paradigm: The study suggests that for APH, systemic tyrosine kinase inhibitors (TKIs) like crizotinib may be superior to local interventions (surgery/radiation) or broad chemotherapy, especially in multi-organ cases.

Key Results

  • Rapid Response: The patient’s nipple ulceration healed within just two weeks of starting crizotinib.
  • Clinical Clearance: Bilateral breast masses disappeared clinically within two months.
  • Complete Remission: Follow-up CT and MRI scans showed total resolution of lesions in the lungs, breast, brain, and bone.
  • Durability: As of the latest follow-up in August 2023, the patient has maintained complete remission for over two years with good drug tolerance and no significant side effects.

Limitations and Future Work

The authors acknowledge several open questions:

  • Resistance Mechanisms: In other ALK-positive cancers (like lung cancer), tumors eventually develop resistance mutations (e.g., L1196M). It is currently unknown if or when APH might develop similar resistance.
  • Treatment Duration: It remains unclear if patients with APH need to stay on ALK inhibitors indefinitely or if the drug can eventually be tapered off.
  • Second-Generation Inhibitors: While crizotinib worked here, the authors note that newer inhibitors like alectinib or lorlatinib might be necessary if the disease progresses or if better central nervous system (CNS) penetration is required.

This report serves as a vital reminder to clinicians: when faced with unusual multi-organ masses, molecular testing for ALK fusions can be the difference between a poor prognosis and a "miracle" recovery.

Summary updated

Abstract

ALK-positive histiocytosis (APH) is a rare type of histiocytic neoplasm with characteristic <i>ALK</i> (Anaplastic Lymphoma Kinase) gene translocation and fusion, with only 27 reported cases in the literature. In this study, we report the first case of synchronous bilateral breast involvement of ALK-positive histiocytosis on initial presentation in a 46-year-old Hispanic woman. APH was diagnosed by the confirmation of clonal histiocyte proliferation with ALK overexpression on IHC and the presence of <i>KIF5B-ALK</i> gene fusion from her breast and lung biopsies. The patient in our study is currently under complete and long-term remission with crizotinib treatment (an ALK inhibitor). This report expands on the clinical manifestation of APH, emphasizes the importance of ALK detection in histiocytic diseases, and provides the efficacy and long-term prognosis of the ALK inhibitor therapy for APH.
BibTeX
@inproceedings{zhou2023case,
  author = {Yuhang Zhou and Marisabel Hurtado-Castillo and Om Pandey},
  title = {{Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib}},
  booktitle = {Frontiers in Medicine},
  year = {2023},
  doi = {10.3389/fmed.2023.1288849},
}
Figure